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ABSTRACT 
The objective of this study was to assess the relative efficacy and tolerability of topical MJ1 compared to 
routine care in the treatment of histologically proven CL. A total of 150 patients with 297 lesions were 
randomly allocated to receive either topical MJ1 agent as a paste to applied to the lesions without cover 
three times a day for 20 days or routine care (intramuscular injection of meglumine antimonate 20 
mg/kg/day for 2 weeks or intralesional 0.5-1CC for a total of four injection with one week interval). The 
primary end point of this study was the clinical cure of the lesion. Response to treatment was assessed at 
1, 2, 3 and 8 weeks after start of therapy. Of the 132 lesions treated with MJ1, the mean size of lesions 
decreased from 423.9 to 30.4 mm
2
, 111 (84.1%) were reduced in size and 21 (15.9%) not responded. 
Correspondingly, in the 165 lesions treated with routine care, the mean size of lesions slightly increased 
from 295.8 to 330.5 mm
2
, 82 (49.7%) were reduced in size and 83 (50.3%) not responded. The 
differences were statistically significant (P<0.001). No sever adverse effect occurred. The findings 
highlight that topical treatment with MJ1 agent was much more effective than routine care and is safe 
and well tolerated.  
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INTRODUCTION 
Cutaneous leishmaniasis (CL) is prevalent in 
the tropical and semitropical regions of the 
world with high disease burden at both 
individual and social levels [1].  It is a major 
public health problem in Iran and is endemic in 
many provinces, and almost all CL cases in Iran 
are caused by L. tropica and L. major [2].  CL 
can progress to formation of papules, nodules, 
plaques and especially ulcers. Although all the 
patients do not need treatment and many lesions 
heal spontaneously, the disease is treated to 
shorten the duration of lesions, decrease the 
morbidity associated with large, chronic ulcer 
and prevent ugly scarring [3]. 
Although there is no optimal treatment, many 
therapeutic modalities have been suggested in 
the treatment of CL, and pentavalent antimony 
compounds are considered as the most effective 
drug of choice for it so far and could be 
associated with severe side effects and 
significant discomfort [4]. Currently available 
treatment is not fully effective, safe, cheap, 
requiring systemic or intralesional injection, and 
the large daily volume required is difficult to 
administer intramuscularly [3-5]. An ideal 
treatment for CL should be rapidly effective, 
easily administered, cheap, available at all times 
and should have no side effects. However, new 
safe and economical treatments for it are still 
needed. Several topical therapies have been 
tested and found to be effective [2, 6-9]. MJ1 
(standing for the first version of the drug 
developed by Mohsen Janghorbani) is a non-
synthetic dairy origin agent. It is cheap, easily 
administered, available at any time and has no 
side effects. Although antileishmanial properties 
of MJ1 have been shown in traditional 
medicines a clinical trial has not previously 
been conducted. A pilot study showed that MJ1 
caused immediate death of Leishmania parasites 
when added either directly on a slide or to a 
culture of the parasite. Also, MJ1 was pre-tested 
in few candidate patients with CL as a pilot 
study and was very effective and safe treatment.   
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The aim of this study therefore was to undertake 
a randomized trial of patients with histologically 
proven CL comparing routine care and topical 
MJ1 to determine the best regimen for treatment 
of CL in Iran and to widen therapeutic options.  
 
PATIENTS AND METHODS 
Patients 
Patients who sought treatment for suspected CL 
at our local primary health clinics (Shahinshar 
and Natanz, Iran), between September 2013 and 
October 2014 and not received any treatment 
were evaluated and direct smears for 
leishmaniasis were prepared.  Patients were 
eligible for the study if they had CL that was 
proved parasitologically for a duration of less 
than three months, no previous treatment, no 
serious concomitant medical problems such as 
heart, kidney, liver, endocrinologic, hemato-
logic disease, or serious infection other than 
CL- that were indicated by the medical history, 
willing to participate and availability for follow-
up for two months, and gave informed consent  
(by the patient or his/her parent/guardian in 
cases younger than 18 years) to participate in 
the study. Patients were excluded if they were 
pregnant or lactating women, had duration of 
lesion more than three months and history of 
receiving treatment or allergy to meglumine 
antimonite (Meglusan), presence of secondary 
bacterial infection of the lesion according to 
clinical appearance and occurrence of a serious 
adverse event and presence of > 6 lesions.  The 
study was reviewed and approved by the Ethical 
Review Committee of Isfahan University of 
Medical Sciences. The nature of the trial was 
explained to the patient or parents/legal 
guadians of minors (younger than 18 years old) 
and his/her informed consent obtained.  The 
study complied with the Declaration of 
Helsinki. This trial is registered on Iranian 
Registry of Clinical Trials (www.irct.ir) IRCT-
2013092414746N1. 
Randomization scheme. A total of 150 
participants who met the inclusion criteria were 
assigned randomly and equally to one of the two 
treatment groups. Patients were randomized 
according to a preexisting list produced by a 
computer program that differed from a random 
number generator only in that it assigned equal 
numbers of patients into each treatment group. 
The first treatment group received daily intra-
muscular injection of meglumine antimoniate 
(Meglusan; 5 ml, registered trade name of 
Sterop, Pharmaceutical Company, Belgium), at 
a dose of 20mg/kg, for a total of 2 weeks (112 
lesions) or intralesional 0.5-1CC for a total of 
four injection with one week interval (53 
lesions), according to the Iranian Ministry of 
Health and Medical Education guidelines. The 
second group received topical MJ1 agent as a 
paste applied to the lesions without cover three 
times a day for 20 days and were monitored 
closely by trained medical doctors during the 
course of the study. The MJ1 is a non-synthetic 
dairy origin agent that used as a traditional 
medicine in some part of Iran and contain lactic 
acid, NaCl, calcium, and some protein stabilized 
in a base using 1% carbopol 924 polymer, 25% 
methyl paraben, 5% glycerin, 0.5% triethanol 
amine and 68.5% deionized distilled water. All 
patients had a pre-treatment evaluation that 
consisted of obtaining demographic data, 
duration of symptoms and previous treatment, 
and examination of lesion(s) that included their 
location, number of lesions, duration, diameters, 
and type of lesion such as nodule, papule, 
plaque, ulcer and scaling and the lesions were 
photographically recorded. 
Parasitological diagnosis 
One lesion on each patient was parasitologically 
examined. It is important to note that the 
diagnosis of leishmaniasis was made by the 
visualization of amastigotes in smears of lesion 
material. The organisms were not routinely 
cultured from the material and as almost all CL 
observed in this province is due to L. major, 
polymerase chain reaction tests were not done. 
Patient evaluation: The trial was discerning in 
that both patient and doctor were aware that the 
patient was receiving treatment. Patients 
admitted into the trial were given either 
unlabeled boxes containing MJ1 paste and 
instructed to apply them on the lesions without 
cover three times a day for 20 consecutive days 
or administered intramuscularlly 20mg/kg of 
Meglusan for a total of 2 weeks or intralesional 
0.5-1CC for a total of four injection with one 
week interval. Patients were evaluated at 1, 2, 3, 
or 8 weeks after the start of therapy. The lesions 
were remeasured at the baseline and at these 
follow-up visits (lesions were measured by two 
dimensions in mm, and their area was calculated 
as if they were rectangles). The size was 
assessed by marking the lesion and measuring 
its diameter. Clinical evaluation of all lesions 
was made by physicians who know which 
patients had received which treatment.  
Determination of response 
The primary end point of this study was the 
clinical cure of the lesion. The definition of 
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initial healing and definitive cure was based on 
clinical criteria only. Complete healing defined 
as complete re-epithelialization and relief of 
induration, partial improvement defined as more 
than 50% re-epithelialization and decrease of 
induration and size of the lesion, and no 
response to treatment defined as less than 50% 
decrease of induration and size of the lesion or 
worsening of lesion compared with baseline.  
Patients who developed secondary infections 
during treatment were excluded. Patients who 
were removed from the study were treated with 
Meglusan at doses of 20mg/kg/day for 2 weeks.  
Statistical analysis 
The sample size was calculated when the study 
was designed and was based on the comparison 
of two proportions. We calculated that 80 
patients per treatment group would be required 
to provide the study with 80 percent power to 
detect (with a two-sided alpha of 0.05) a 
significant difference in the expected cure rate 
of 80% in patients who received MJ1 and the 
desire cure rate of 60% in those who received 
the routine care at week 8. Appropriate 
statistical analyses were done; independent 
Student’s t-test (for normally distributed 
variables), The Mann-Whitney U test (for not 
normally distributed variables) and chi-square 
or Fisher’s exact test were used to determine the 
significance. All statistical tests were two-sided, 
and P<0.05 was considered statistically 
significant. The analyses were undertaken using 
SPSS version 18.0 for Windows (SPSS Inc., 
Chicago, IL, USA).  
 
RESULTS 
A total of 176 consecutive patients were 
recruited. Thirteen patients refused to 
participate, and 3 patients did not meet our 
study criteria. Thus, 160 patients were 
randomized: 80 in the MJ1 and 80 in the routine 
care. Ten patients were not included in the 
intention-to-treat analysis: 5 patients lost to 
follow-up and 2 patients discontinue treatment 
in the routine care group and 3 patients lost to 
follow-up in MJ1 group (Fig. 1).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1:Design of the study. 
 
Of the remaining 150 patients, 89 (59.3%) were 
male with 178 lesions and 61 (40.7%) were 
female with 119 lesions. Differences in 
distribution of several characteristics among 77 
(43 males and 34 females) are patients in MJ1 
group and 73 (46 male and 27 female) patients 
in routine care group with 297 lesions are 
shown in Table 1. There was no difference 
between treatment groups regarding gender, 
age, number of lesions per patients, and 
distribution of lesions and baseline size of 
lesions. Routine care group had more popular 
lesions while MJ1 group had more lesions in 
form of ulcer (P<0.05). Patients in the MJ1 
group had lower total number of lesions than 
patients in routine care group (P<0.05). All of 
the 150 patients completed their treatment 
without interruption and were available for 
follow-up at 1, 2, 3, or 8 weeks. Mean (SD) 
ages of MJ1 and routine care groups were 28.2 
Assessed for eligibility (n=176) 
Randomized (n=160) 
Completed (n=77) 
Excluded (n=8) 
Not meeting inclusion criteria (n=3) 
Refused to participate (n= 5) 
 
 
 
Enrollment 
Allocated to MJ1 group (n= 80) 
Received allocated intervention 
(n= 77) 
Did not received allocated 
intervention (n=3) 
  
Allocated to routine care group 
(n= 80) 
Received allocated intervention 
(n= 73) 
Did not received allocated 
intervention (n=7) 
 
Completed (n=73) 
Excluded (n=7) 
Lost to follow-up (n=5) 
Discontinue intervention (n= 2) 
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(19.7) and 29.5 (17.7) years, respectively. The 
average numbers of lesions per patient in MJ1 
and routine care groups were 1.9 (1.2) and 2.3 
(2.0) respectively. The duration of the disease in 
all cases was less than three months. Most 
patients in MJ1 (89.6%) and routine care 
(82.2%) groups had less than three lesions. The 
most common sites of involvement were the 
face and the extremities.  
Table 1: Characteristics of patients with cutaneous leshmaniasis by treatment group. 
 
 
Characteristics 
Treatment group 
MJ1    
N= 77 
Mean (SD) 
Routine care  
N=73 
Mean (SD) 
Differences 
(95% CI) 
Age  (years) 28.2 (19.7) 29.5 (17.7) -1.2 (-7.3, 4.8) 
No. of lesions/patients 1.9 (1.2) 2.3 (2.0) -0.4 (-0.9, 0.2) 
Lesion size (mm2) at 
baseline 
423.9 (713.9) 295.8 (512.2) 128.1 (-17.4,  273.5) 
 No. (%) No. (%)  
Total no. of lesions 132 (44.4) 165 (55.6) -11.2 (-19.1, -3.1)* 
Gender    
Male 43 (55.8) 46 (63.0) -7.2 (-22.8, 8.5) 
Female 34 (44.2) 27 (37.0) - 
Distribution of lesions    
Upper limbs 64 (48.5) 77 (46.7) 1.8 (-9.6, 13.2) 
Lower limbs 51 (38.6) 66 (40.0) -1.4 (-12.5, 9.8) 
Face 11 (8.3) 9 (5.5) 2.8 (-3.8, 8.7) 
Trunk 6 (4.6) 13 (7.9) -3.3 (-8.8, 2.1) 
Type of lesions    
Nodule 12 (9.1) 13 (7.9) 1.2 (-5.2, 7.6) 
Papule 98 (74.2) 141 (85.5) -11.3 (-20.4, -2.0)* 
Ulcer 22 (16.7) 11 (6.7) 10.0 (2.6, 17.4)* 
CI =Confidence interval. *P<0.05, **P<0.01, **P<0.001 for the difference in the mean and proportion of the variables between 
MJ1 and routine care.  
 
Of the 132 lesions treated with MJ1 after 8 
weeks of follow-up, the mean size of lesions 
decreased from 423.9 (95% confidences interval 
(CI): 301.0, 547.0) mm
2
 to 30.4 (95% CI: 21.7, 
39.1) mm
2
. Correspondingly, in the 165 lesions 
treated with routine care, the mean size of 
lesions increased from 295.8 (95% CI: 217.0, 
375.0) to 330.5 (95% CI: 289.0, 372.0) mm
2
. 
Mean lesion size at baseline and after the first 
week did not differ between the MJ1 and 
routine care groups, but after the second week, 
mean lesion size was significantly lower in MJ1 
group (Table 2). 
 
Table 2: Comparison of lesion size in 150 patients with 297 cutaneous leishmaniasis lesions before and after treatment with MJ1 
and Meglusan. 
 Treatment group Differences (95% CI) 
 MJ1 
Mean (SD) 
Routine care 
Mean (SD) 
Number of lesions at baseline   132 (44.4) 165 (55.6) - 
Lesion size (mm2) at baseline   423.9 (713.9) 295.8 (512.2) 128.1 (-17.4,  273.5) 
 Lesion size (mm2) at 1st  week  310.4 (565.6) 271.2 (463.3) 39.2 (-81.0, 159.4) 
 Differences (95% CI) 113.5 (66.3, 160.8)*** 24.6 (-1.1, 50.5) - 
Lesion size (mm2) at 1st  week 310.4 (565.6) 271.2 (463.3) - 
Lesion size (mm2) at 2nd  weeks  164.7 (418.1) 266.3 (341.9) -101.6 (-189.0, -14.2)* 
Differences (95% CI) 145.7 (89.5, 202.9)*** 4.9 (-31.9, 41.7) - 
Lesion size (mm2) at 2nd  weeks   164.7 (418.1) 266.3 (341.9) - 
Lesion size (mm2) at 3rd weeks 88.0 (174.3)  254.3 (372.7) -166.3 (-244.9, -
87.7)*** 
Differences (95% CI) 76.7 (52.3, 101.0)*** 12.0 (-33.3, 57.3) - 
Lesion size (mm2) at 3rd weeks 88.0 (174.3)  254.3 (372.7) - 
Lesion size (mm2) at 8th weeks  30.4 (50.6) 330.5 (268.0) -300.1 (-434.5, -
165.6)*** 
 Differences (95% CI) 57.6 (-5.4, 121.0) 76.2 (-154.0, 1.3)- - 
*P<0.05, **P<0.01, ***P<0.001. CI= confidence interval. 
A reduction in lesion size was observed in 
91.7% (121/132) of patients during MJ1 
treatment and in 83.0% (137/165) of patients 
during routine care treatment (χ2=4.8, P<0.05) 
after the first week. After the second week, a 
reduction in the lesion size was observed in 
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93.9% (124/132) of patients during MJ1 
treatment and in 68.9% (111/161) of patients 
during routine care treatment (χ2 test =28.5, 
P<0.001). After the third week, a reduction in 
the lesion size was observed in 89.7% (96/107) 
of patients during MJ1 treatment and in 67.3% 
(72/107) of patients during routine care 
treatment (χ2 test =15.9, P<0.001). After the 
eight week, a reduction in the lesion size was 
observed in 100.0% (26/26) of patients during 
MJ1 treatment and in 66.7% (12/18) of patients 
during routine care treatment (χ2 test=10.0, 
P<0.01) (Table 2).  
Eight weeks after start of treatment, the size of 
77 of the 165 lesions (46.7%; 95% CI: 39.1, 
54.3) treated with routine care was reduced and 
it not responsed in 88 (53.3%; 95% CI: 45.7, 
60.9). Correspondingly, the size of 110 of 132 
lesions (83.3%; 95% CI: 77.0, 89.7) treated with 
MJ1 was reduced and 22 (16.7%; 95% CI: 10.3, 
23.0) not responsed. The differences were 
statistically significant (P<0.001). Complete 
response was seen in 40.9% and 9.1%, partial 
response in 42.4% and 37.6%, and no response 
in 16.7% and 53.3% of the patients in the MJ1 
group vs. routine care group, respectively. 
Therefore, the response rate in MJ1 group was 
much superior to that of the routine care group 
(P<0.001; Table 3). 
 
Table 3: Response of lesions to treatment 8 weeks after initiation of the treatment. 
Response MJ1 
No. (%) 
Routine care 
No. (%) 
Difference  
(95% CI) 
Total lesions  
Number of lesions 132 (44.4) 165 (55.6) - 
Complete recovery 54 (40.9) 15 (9.1) 31.8 (22.4, 41.3)* 
Partial recovery 56 (42.4) 62 (37.6) 4.8 (-6.4, 16.1) 
No response 22 (16.7) 88 (53.3) -36.7 (-46.6, -26.7)* 
Non-ulcerated 
lesions 
   
Number of lesions 110 (83.3) 154 (93.3) - 
Complete recovery 44 (40.0) 14 (9.1) 30.9 (20.7, 41.1)* 
Partial recovery 44 (40.0) 54 (35.1) 4.9 (-6.9, 16.4) 
No response 22 (20.0) 86 (56.8) -35.8 (-46.7, -25.0)* 
Ulcerated lesions    
Number of lesions 22 (16.7) 11 (6.6) - 
Complete recovery 10 (45.5) 1 (9.1) 36.4 (9.5, 63.2)* 
Partial recovery 12 (54.4) 8 (72.7) -18.2 (-51.7, 15.4) 
No response 0 (0.0) 2 (18.2) -18.2 (-41.0, 4.6) 
*P<0.001, CI=confidence interval 
Eight weeks after start of treatment, complete 
response in non-ulcerated lesions was seen in 
40.0% and 9.1%, partial response in 40.0% and 
35.1%, and no response in 20.0% and 56.8% of 
the patients in the MJ1 group vs. routine care 
group, respectively. The difference in response 
rates was statistically significant between two 
treatment groups in non-ulcerated lesions 
(P<0.001). 
A total of 33 patients (22 in MJ1 group and 11 
in routine care group) had ulcerated lesions and 
complete response in ulcerated lesions was seen 
in 45.5% and 9.1%, partial response in 54.4% 
and 72.7%, and no response in 0.0% and 18.2% 
of the patients in the MJ1 group vs. routine care 
group, respectively. The difference in complete 
recovery was statistically significant between 
two treatment groups in ulcerated lesions 
(P<0.001), but the difference in partial recovery 
and not respond was not statistically significant 
between two treatment groups in ulcerated 
lesions (P>0.05), probably due to the small 
number of ulcerated lesions. 
MJ1 treatment was tolerated well and did not 
lead to discontinuation of treatment. The only 
observed adverse events were slight burning, 
which occurred in about 50% of patients with 
ulcerated lesions. 
 
DISCUSSION 
In Iran, during the study period, the standard 
first line treatment for CL was meglumine 
antimoniate (Meglusan). During the last two 
decades clinical trials in the search of new 
treatments for CL have been developed [10-14], 
but some of them have not been effective and 
there is not enough evidence about the 
effectiveness for others. In different parts of 
Iran, various combinations of herbal and animal 
origin medicine have been used for the 
treatment of CL [7]. Treatment regimens that 
involve parenteral and interalesional injection 
and that exposed patients to untoward side 
effects may not only be inconvenient but also 
unnecessary. Topical treatment of CL is thus 
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desirable. In the present study, we assessed 
response to early healing of lesions and found 
that MJ1 agent was more effective than 
intramuscular or intralesional injection of 
meglumine antimoniate. This trial is the first 
clinical evidence on efficacy of MJ1 in patients 
infected with CL. No unusual or unexpected 
safety risks were found with MJ1 therapy in our 
study population. 
The efficacy of intralesional versus 
intramuscular administration of Glucantime was 
studied in Saudi Arabia and no statistically 
significant differences was noted between the 
two treatment groups [15]. The efficacy of 
interalesional injection of meglumine 
antimoniate alone in the treatment of lesions of 
CL due to L.major, 6 weeks after initiation of 
this intervention, was different from 26.0% to 
86.7% in previous studies [16-21]. In the 
present study, response to meglumine 
antimoniate was relatively low and was not 
effective because of their adverse effects, high 
cost, and emergence of drug resistance. 
Meglumine antimonate has been associated with 
several disadvantages such as need for 
parenteral route, discomfort, and the presence of 
various side effects (fatigue, vomiting, anorexia, 
muscle and abdominal pain, cardiac 
abnormalities, increased hepatic 
aminotransferase, pancreatitis, renal toxicities) 
[10, 11]. For special populations such as 
pregnant women, children, or patients to whom 
pentavalent antimony compounds is 
contraindicated, the development of a new safer 
therapeutic options are needed 
The dairy extract used in this study was in the 
form of a crude paste. The possible mechanisms 
of action of MJ1 agent in CL is unknown. 
Further studies must be undertaken to determine 
the possible effective ingredients which are 
important in the recovery of the lesions.  
Although, this study is only controlled trials to 
date of effect of MJ1 agent on the CL the trial 
was carried out in primary care clinics with 
referral system. Patients could drop out at any 
time and seek another treatment in any other 
public or private health institution. In such a 
setting, patients usually do not come for follow-
up if they feel that their condition is not 
improving, or sometimes even their condition 
improved. For these reasons although a much 
longer follow-up period was needed to 
adequately assess treatment efficacy of MJ1, it 
was not possible in this study. So, selection and 
volunteer bias cannot be ruled out. Patient 
compliance was not a problem in this study 
since almost all patients presented for follow-
up. CL is a self-healing disease and, in most 
cases, heals spontaneously in less than one year. 
The follow-up period in present study was 8 
weeks and the duration of disease in all cases 
was less than three months. Therefore, the total 
time for the trial was well below the time 
needed for self-healing for both species of CL in 
our country.   
Although the value of the double blind, 
controlled trial is widely recognized, this design 
is not always appropriate or indicated. Because 
of the different side-effect profile of pentavalent 
antimony compounds and MJ1 administered as 
a paste and meglumine antimoniate 
intramuscularly or intralesionally, it would have 
been impossible to keep patients blinded in a 
study of this nature. Similarly, treating 
physicians dealing with clinical and laboratory 
adverse events can easily become discerning. 
However, Schultz and co-workers reported that, 
to avoid bias in clinical trials, careful 
randomization is more important than a double-
blind design [22].  
 As this study indicated that MJ1 was superior 
to meglumine antimoniate, we did a pilot study 
before this study to assess the applicability of 
those results to CL [23]. The encouraging 
results obtained in this trial warrant further 
studies, a larger scale, probably blinded, trial is 
needed.  
We conclude that MJ1 compound was more 
effective than intramuscular or intralesional 
injection of meglumine antimoniate and was 
safe and well tolerated. Since it was rapidly 
effective, easily administered, painless, cheap, 
available at all times and had no side effects, it 
is recommended as an alternative treatment 
option, especially in patients with history of 
cardiac, renal, hepatic disease and in patients 
not tolerating meglumine antimoniate for any 
reason. MJ1 is much less expensive than 
meglumine antimoniate and more available in 
developing countries where leishmaniasis is 
prevalent. Another advantage of MJ1 over 
alternative treatments is the route of 
administration of this drug, which is topically 
administered. 
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